Biocryst Pharmaceuticals (BCRX) EBT Margin (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly EBT Margin came in at 460.84% in Q1 2026, down 46136.0% YoY from N/an in Q1 2025, and down 101.32% on a QoQ basis from 35030.65% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) EBT Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of EBT Margin data on file, last reported at 460.84% in Q1 2026.
- Quarterly EBT Margin fell 46136.0% year-over-year to 460.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 94.65% (down 8448.0% YoY) and the FY2025 annual result came in at 30.56%, up 4986.0% from the prior year.
- EBT Margin retreated to 460.84% in Q1 2026, from 35030.65% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 35030.65% in Q4 2025 to a low of 460.84% in Q1 2026.
- A 5-year average of 1990.89% and a median of 41.29% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2025 — EBT Margin soared 3505041 bps — and 2026, when it plunged 46136 bps.
- Tracing BCRX's EBT Margin over 5 years: stood at 89.84% in 2022, then climbed by 25 bps to 67.62% in 2023, then soared by 71 bps to 19.76% in 2024, then jumped by 177381 bps to 35030.65% in 2025, then plunged by 101 bps to 460.84% in 2026.
- The last three EBT Margin figures came in at 460.84% (Q1 2026), 35030.65% (Q4 2025), and 7.61% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 36.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.41% |
| Mar 31, 2026 | -460.84% |
| Dec 31, 2025 | 35,030.65% |
| Sep 30, 2025 | 7.61% |
| Jun 30, 2025 | 3.97% |
| Mar 31, 2025 | 0.52% |
| Dec 31, 2024 | -19.76% |
| Sep 30, 2024 | -11.48% |
| Jun 30, 2024 | -11.43% |
| Mar 31, 2024 | -37.75% |
| Dec 31, 2023 | -67.62% |
| Sep 30, 2023 | -41.29% |
| Jun 30, 2023 | -90.42% |
| Mar 31, 2023 | -76.57% |
| Dec 31, 2022 | -89.84% |
| Sep 30, 2022 | -54.07% |
| Jun 30, 2022 | -88.51% |
| Mar 31, 2022 | -148.06% |
| Dec 31, 2021 | -32.92% |
| Sep 30, 2021 | -143.44% |